Industry News
Pharmaceutical Industry News
Quotient Sciences, a CDMO that…
Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat
Henrietta Lacks’s Family Settles Suit With Novartis Over Use of Her Cells
Ms. Lacks’s family accused Novartis of profiting from her cells, which were taken from her without her consent in 1951, when she was dying of cervical cancer.
Several Big Pharmas have…
Several Big Pharmas have introduced their own podcasts to advance corporate branding efforts, while health-focused nonprofits have found in podcasts an effective awareness-raising tool with a relatively low barrier of entry in terms of production
In a Worker Adjustment and…
In a Worker Adjustment and Retraining Notification Act alert filed this week, Merck revealed that it is laying off 147 staffers at a vaccine manufacturing plant in Durham. The cuts are a result of Merck's
A handful of pharmas and…
A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation for a long-lasting awareness push.
While the FDA has flip-flopped on…
While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with a positive recommendation from the CHMP.
Two years and five indications…
Two years and five indications later, UCB's immunology blockbuster Bimzelx is halfway to the company's initial goal of at least 4 billion euros ($4.4 billion) in peak sales.
As one long-running feud over the…
As one long-running feud over the controversial generic drug carve-out known as “skinny” labeling comes to a close, the U.S.’ top lawyer is urging the Supreme Court to reverse a recent decision on another, arguing
China assets have outgrown a…
China assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, Evaluate said. Daiichi Sankyo named former Novartis exec John Tsai, M.D., as its new R&D head.
Fierce Pharma’s Angus Liu speaks…
Fierce Pharma's Angus Liu speaks with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former FDA oncology division director, about a recent article from agency officials outlining how the FDA plans
In this webinar, which is a…
In this webinar, which is a rebroadcast from the 2025 PODD Conference, business development and technology assessment professionals actively involved in the scouting and evaluating of novel delivery technologies, discuss the constantly evolving topic of partnering.
This webinar addresses how…
This webinar addresses how pharmaceutical organizations are expanding their clinical trial operations globally to support evolving portfolios and react to geopolitics.
Patients and caregivers share…
Patients and caregivers share their perspectives on their clinical trial experiences to help industry with future trial optimization and accessibility.
Why Estrogen Patches For Menopause Are So Hard to Find
Changing attitudes around menopause treatment have driven up demand for hormone therapy.
Less than six months after…
Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly widened its reach into the first-line setting
Following an unexpected delay of…
Following an unexpected delay of the CDC vaccine panel's February meeting, the Advisory Committee on Immunization Practices (ACIP) has selected dates next month to convene and discuss, among other matters, COVID-19 vaccine safety.
Already on a roll with its…
Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular myasthenia gravis.
With a new online resource, Eisai…
With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer diagnosis.
Sarepta Therapeutics CEO Doug…
Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ironic twist of fate” involving the health of his family.
Viatris’ three-year reorganization…
Viatris' three-year reorganization will affect staffers in a range of functions including the company's commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.